Hydrogen Water and Bone Health: What the Recent Research Suggests About Osteoporosis, Fracture Healing, and Aging Bone

An atypical femoral fracture is one of the rarer, harder problems in orthopedics. It is the kind of break that shows up after years on a bisphosphonate — the drug class most often prescribed for osteoporosis — and the kind that, paradoxically, can fail to heal on schedule because the same drug suppressing the breakdown of bone is also slowing the remodeling the fracture needs. In May 2026, a Hong Kong research team set out to ask whether hydrogen-rich water could change that. They induced atypical femoral fractures in ovariectomized osteoporotic rats already on zoledronate, randomized the animals to hydrogen-rich water or controls, and tracked what happened inside the fracture gap. An and colleagues (2026), writing in Biomaterials, reported that hydrogen-rich water resolved the non-union gap and promoted callus bridging — not by pushing bone formation harder, but by clearing the senescent, pro-inflammatory cells that had stalled the repair.

That kind of result is part of a larger shift in how researchers have been asking bone questions. The studies on hydrogen and the skeleton are no longer one-off animal trials. Over the last twenty-four months, multiple independent groups in Hong Kong, mainland China, Italy, and Japan have published bone work using different models — atypical fracture, steroid-induced osteonecrosis, high-altitude bone degeneration, glucocorticoid-driven osteoporosis, alveolar bone loss, microgravity. Different teams, different models, similar shape of result. None of them is a finished case. All of them are worth reading carefully before any product makes a bone-health claim.

The Bone Question Researchers Started Asking

Bone is not the still object it looks like on an X-ray. It is a living tissue that turns over constantly. Osteoclasts dissolve old bone. Osteoblasts lay down new bone. The two processes are supposed to stay roughly balanced across a lifetime — which is how a skeleton that is rebuilt every ten years stays mostly the same shape and density. When that balance tips toward more dissolution than formation, the result is bone loss. Across a long enough time horizon, that is osteoporosis.

Where bone loss actually starts

The clinical picture — the broken hip, the wrist fracture from a fall, the vertebral compression that quietly steals an inch of height — is the late chapter. The earlier chapter, the one researchers have been increasingly interested in, is the cellular environment. A bone that is losing density is not just a bone with fewer osteoblasts. It is a bone whose marrow has shifted toward inflammation, whose senescent cells are sending out signals that suppress new bone formation, and whose mitochondrial redox balance is off. The deeper the bone-aging research has gone, the more it has converged on a redox story.

Oxidative stress and the silent half of bone biology

Reactive oxygen species are not all bad. The osteoclast, the cell that resorbs bone, actually uses a controlled oxidative burst as part of its normal function — it is how it dissolves the mineral matrix it sits on. The problem starts when the oxidative tone of the bone microenvironment rises beyond signaling levels. Researchers have documented elevated mitochondrial ROS in bone tissue from estrogen-deficient animals, from glucocorticoid-exposed animals, from hypoxic animals, and from aged animals. The pattern they describe is consistent: too much oxidative stress drives osteoclast over-activation, accelerates osteocyte apoptosis, suppresses osteoblast differentiation, and tilts the balance toward bone loss. That redox tilt is the door researchers have been knocking on with molecular hydrogen.

The 2026 Atypical-Femoral-Fracture Study, Reported Carefully

The headline result from An et al. (2026) in Biomaterials is worth restating precisely, because the study is preclinical and the model is specific. The researchers worked in ovariectomized rats — a standard animal model for postmenopausal bone loss — that were then administered zoledronate, the most potent bisphosphonate, to mimic the long-term drug exposure that precedes an atypical fracture in human patients. The animals were then given a unilateral femoral fracture, and randomly assigned to receive hydrogen-rich water or control water during the healing window.

The model the researchers built

The setup is built to reproduce a specific clinical paradox: the bone is dense, drug-suppressed, and brittle. It fractures. And then it fails to heal — because the very pathway the bisphosphonate suppresses (osteoclast-mediated remodeling) is one the fracture callus normally relies on. Atypical femoral fractures in human patients can sit in delayed union or non-union for months. The Hong Kong group's question was whether hydrogen-rich water, given concurrently, could change that.

What hydrogen-rich water did inside the fracture gap

The micro-CT and biomechanical data the authors report tell a clean story. The hydrogen-rich water group resolved the non-union gap and showed bridged callus where the zoledronate-only group still showed persistent fibrous tissue. The mechanical strength of the underlying bone — which the bisphosphonate had elevated — was not compromised by the hydrogen-rich water intervention. The histology and immunostaining went further. Inside the fracture gap, the researchers reported a reduction in senescence markers (SA-β-gal activity, p16, p21), a clearance of pathological fibroblasts, a shift in macrophage polarization from pro-inflammatory M1 toward anti-inflammatory M2, and a restoration of the type-H vessels that osteogenesis depends on.

Senescence clearance versus bone-formation boosting

The authors are careful about the framing. They are not arguing that hydrogen-rich water is anabolic — that it makes bone-forming cells work harder. They are arguing something subtler: hydrogen-rich water reshaped the senescent microenvironment that had stalled the repair, and once that microenvironment was reset, the body's normal regeneration program could finish the job. That distinction matters. A drug that pushes bone formation is one strategy. A drug that clears the cellular obstacles to a body's own repair is a different strategy. The latter is closer to how aging biology generally thinks about durable tissue repair, and it lines up with how researchers in the senolytic field have been positioning anti-senescence approaches.

Why the Selective-Antioxidant Story Maps onto Bone at All

What "selective" actually means here

The conceptual basis for any of these results traces back to Ohsawa and colleagues (2007), who proposed in Nature Medicine that molecular hydrogen behaves as a selective antioxidant — preferentially reacting with the hydroxyl radical and peroxynitrite, the two most damaging reactive oxygen species, while leaving the lower-energy oxidants the body uses for signaling largely alone. That hypothesis is still a working framework rather than a closed case. But it is the framework every recent bone paper draws from, and it explains why bone tissue is a plausible target.

Why a non-selective antioxidant would be the wrong tool

The osteoclast needs its controlled oxidative burst to do its job; an antioxidant that quenches everything would impair normal bone turnover. An antioxidant that quenches only the most damaging species, only when their concentration spikes, would in principle leave normal physiology alone while suppressing the runaway inflammation that drives pathological bone loss. That is what the working hypothesis predicts. Whether it holds in human patients is a separate question, and one that the published trials have only begun to ask.

Microgravity, Astronauts, and a Foundational 2013 Paper

One of the earliest and most-cited bone studies on hydrogen comes from a research model nobody else was using at the time. Sun et al. (2013), publishing in Osteoporosis International, took Sprague-Dawley rats and put them through six weeks of hindlimb suspension — the standard ground-based model for the bone loss astronauts experience in zero-gravity. They simultaneously gave the rats hydrogen-rich water and measured bone mineral density, mechanical properties, and cellular markers in the femur and lumbar vertebrae.

A model designed to mimic microgravity bone loss

Six weeks in the suspension model produces measurable bone loss — lower bone mineral density, lower ultimate load, lower stiffness — in both the femur and the lumbar vertebrae. It is one of the cleanest non-disease models of bone loss researchers have, because the cause is mechanical unloading rather than a metabolic or hormonal disruption. That made it a useful test bed for asking whether an antioxidant intervention could blunt the resulting damage.

What the data showed

The hydrogen-water group, the researchers reported, retained more bone mineral density, more ultimate load, and more energy absorption capacity at both femur and lumbar vertebrae than the suspended controls. Inside the bone tissue, malondialdehyde and peroxynitrite levels were lower, and total sulfhydryl content was preserved — three independent markers pointing in the same direction. In cultured osteoblast precursor cells exposed to modeled microgravity, hydrogen-rich medium blunted ROS formation, restored osteoblast differentiation, and lowered the receptor-activator-of-nuclear-factor-kappa-B-ligand-to-osteoprotegerin ratio — the molecular signal that pushes osteoclast activation. The authors framed hydrogen as a possible nutritional countermeasure for spaceflight-related bone loss, and called for human studies. More than a decade later, those human studies have still not been done in astronauts. But the paper remains the foundational entry in the hydrogen-and-bone literature.

Zebrafish Scales and Steroid-Induced Bone Loss

A 2023 paper from the IRCCS Orthopedic Institute Galeazzi in Milan introduced an unusual model. Carnovali and colleagues (2023), publishing in Antioxidants, used zebrafish scales as a system for studying glucocorticoid-induced bone loss. The scale is not a vertebrate bone in the human sense, but it is a real mineralized tissue that responds to osteoclast and osteoblast activity in the same fundamental way — and it is far easier to monitor than mammalian bone. Treating the fish with prednisolone produced a reproducible bone-loss phenotype, with increased osteoclast activity and decreased osteoblast activity.

The treatment-group fish received hydrogen-rich water. The researchers reported that hydrogen-rich water prevented osteoclast activation and the resulting bone loss, verified by both biochemical and histochemical tartrate-resistant alkaline phosphatase assays. What hydrogen-rich water did not do, in their hands, was rescue the suppressed osteoblast activity — so the protective effect was specifically on the resorption side. They also reported that hydrogen-rich water did not facilitate repair of the resorption lacunae prednisolone had already produced. The picture the authors offered was of hydrogen as a possible preventive — useful before bone damage accumulates, more limited in reversing damage already done.

Hypoxia, High Altitude, and the Gut-Bone Axis

A 2025 paper from Qinghai University, working at one of the world's leading high-altitude medicine institutes, introduced a different mechanistic angle. Zhu and colleagues (2025), publishing in the journal Bone, exposed mice to a simulated 5,500-meter altitude for four months and tracked the progressive bone deterioration that resulted. They then asked whether hydrogen-rich water could blunt it, and where in the body the protective effect actually originated.

Where the gut microbiota enters the story

The hypoxia-exposed control mice showed exactly what the high-altitude bone literature predicts: lower bone density, elevated HIF-1α expression in bone tissue, elevated RANKL and TRAP — markers of osteoclast activation — and suppressed Nrf2, the master redox-regulator transcription factor. The hydrogen-rich water group showed measurable preservation of bone structure and reduced multi-organ damage in the liver, lungs, kidneys, and colon. The mechanistic finding that surprised the researchers was that hydrogen-rich water did not directly normalize HIF-1α, RANKL, or Nrf2 in the bone tissue itself. The signaling shift happened somewhere else first.

A different kind of bone-protection mechanism

The somewhere else turned out to be the gut. The hypoxic mice had a measurably disrupted gut microbiota — lower diversity, a fall-off in beneficial Lactobacillus species, an unbalanced ratio of aerobic and anaerobic bacteria. Hydrogen-rich water partially reversed this dysbiosis, and that microbiota rebalancing tracked with reduced systemic inflammation and oxidative stress, which in turn tracked with bone preservation. The authors framed their result as a possible "gut-bone axis" mechanism — hydrogen-rich water acting through the gut to relieve a systemic inflammatory load that the bone then benefits from, rather than acting directly on bone-cell signaling pathways. That is a different mode of action than the senescence-clearance picture in the atypical fracture paper, and the two are not mutually exclusive.

Steroid-Associated Osteonecrosis and the ACOD1-Itaconate Pathway

A 2025 paper from the same Hong Kong group behind the atypical fracture study took on a different orthopedic problem. An and colleagues (2025), publishing earlier in Biomaterials, used a mouse model of steroid-associated osteonecrosis — the bone death that follows long-term high-dose glucocorticoid therapy. The condition has very few effective preventive options in clinical orthopedics. Hydrogen-rich water was added to the drinking water of one group; the rest were maintained on standard care.

Across multiple readouts, the hydrogen-rich water group showed reduced osteocyte apoptosis, improved trabecular architecture, more osteoblasts, fewer osteoclasts, lower TNF-α, and better blood perfusion to the bone tissue. The macrophage polarization shifted from M1 toward M2 — the same shift the 2026 fracture paper would later report. RNA sequencing in the bone tissue identified upregulation of ACOD1 — a gene encoding an enzyme that produces itaconate, a metabolite that has emerged in the immunometabolism literature as an anti-inflammatory signaling molecule. Supplementation with dimethyl itaconate alone reproduced much of the hydrogen-rich water effect, supporting the pathway as causal. The authors framed hydrogen-rich water as acting through immunometabolic reprogramming rather than direct redox-quenching — a more specific mechanism than the field had previously assigned to hydrogen in bone.

Alveolar Bone, Obesity, and a 2017 Drinking-Water Study

One of the earlier mammalian studies on hydrogen and bone came from the dentistry literature, where alveolar bone — the jaw bone that anchors teeth — is a common readout. Yoneda and colleagues (2017), publishing in Nutrients, fed Fischer rats a high-fat diet to induce obesity, then gave one group hydrogen-rich drinking water and the other group distilled water. The high-fat-diet rats developed elevated gingival oxidative stress (measured as 8-hydroxydeoxyguanosine, a standard marker of oxidative DNA damage) and accelerated alveolar bone resorption — the same shift seen clinically in patients with metabolic disease and periodontitis.

The hydrogen-rich water group, the researchers reported, suppressed body weight gain, lowered gingival 8-OHdG, and reduced alveolar bone resorption measured by micro-CT. The pattern fit the same shape as the larger bone literature — an oxidative-stress-driven bone-loss model, attenuated by hydrogen-rich water in the drinking water, with the effect tracking the oxidative markers. The study did not push the result as a clinical claim. It treated the finding as a hypothesis-generator for the long-suspected link between metabolic health, oxidative stress, and periodontal bone loss. That same gingival-and-alveolar thread is exactly where the research on hydrogen water and oral health picks up — this time in human periodontal trials and a meta-analysis rather than a rat model.

The 6-Month Older-Adults Trial, and Where Bone Sits in It

Most of the bone-and-hydrogen evidence remains preclinical. The closest human trial that sits in the right neighborhood is the long pilot run by Zanini and colleagues (2021), who randomized 40 adults aged 70 and over to six months of hydrogen-rich water or control water. The trial is registered as NCT04430803 and was published in Experimental Gerontology. It is one of the longest and most comprehensive human hydrogen-water trials in the literature.

What the trial actually measured

The protocol included a wide panel of aging biomarkers: telomere length, DNA methylation patterns, brain metabolism by magnetic resonance spectroscopy, cognitive function, body composition, hand-grip and lower-body strength, sleep, and quality-of-life scales. The headline finding was a treatment-by-time interaction on telomere length favoring the hydrogen-water group. Brain-metabolite signals shifted in the hydrogen group as well. Lower-body strength improved in the hydrogen-water group — a finding that is relevant to bone health indirectly, because muscle loading is one of the strongest drivers of bone preservation in older adults. The trial did not measure bone density directly. No adverse events were reported across six months of daily intake in older adults, and the biomarker panel is the kind of distal-but-relevant data the field generally cites when talking about hydrogen and aging. That same trial anchors a closer look at age-related muscle loss, which we cover separately in what the research suggests about hydrogen water and sarcopenia.

What it does not say

It does not show that hydrogen-rich water prevents osteoporosis. It does not show that hydrogen-rich water reverses bone loss. It does not even measure bone mineral density directly. What it shows is that across six months in adults over seventy, a hydrogen-rich-water intervention was reported as well tolerated and was associated with movement in several biomarkers researchers consider relevant to aging biology — including a strength measure that is meaningfully related to bone outcomes. The authors call for a larger, adequately powered confirmatory study. That call has not yet been answered for a bone-specific endpoint, and the cautious read is to keep the human bone-claim ledger at zero until the next trial publishes.

The unfinished half: where human evidence ends

Pulling the bone studies together, the preclinical signal is reasonably stable. Across atypical fracture, microgravity, glucocorticoid-induced osteoporosis, steroid-associated osteonecrosis, hypoxia, and alveolar bone loss, the direction is the same: less oxidative damage, less inflammation, less osteoclast over-activation, and either preservation or partial recovery of bone tissue. A similar preclinical pattern is emerging in hydrogen and reproductive tissue, where 2025–2026 studies have tested hydrogen-rich water against oxidative stress in spermatogenesis and ovarian models. Sometimes the mechanism is direct senescence clearance, sometimes itaconate-mediated immunometabolic reprogramming, sometimes a gut-bone axis route. What the literature has not settled is the human translation. There is no randomized controlled trial of hydrogen-rich water for postmenopausal osteoporosis. There is no human trial of hydrogen-rich water for delayed fracture union. The honest read is that the preclinical signal is consistent and the clinical case is open — the next round of trials is what will close it or change it.

None of this is a treatment plan. The bone studies covered here — atypical fracture, microgravity, steroid-associated osteonecrosis, glucocorticoid-induced osteoporosis, alveolar bone loss, high-altitude bone degeneration — are preclinical, in animal or zebrafish models. The Zanini older-adults trial is the closest human evidence and it touches bone only through strength and aging biomarkers, not bone density. Researchers continue to investigate.

Further Reading

For the broader PubMed literature on hydrogen-rich water and bone, see PubMed's full results for hydrogen-rich water and bone.

• An Y et al. (2026), Biomaterials. PMID: 42143430. The anchor study for this article. In an ovariectomized-rat model of atypical femoral fracture induced by zoledronate, hydrogen-rich water resolved the non-union gap by clearing senescent cells (lower SA-β-gal, p16, p21) and shifting macrophages from M1 toward M2 — not by pushing bone formation harder.
• An Y et al. (2025), Biomaterials. PMID: 40411985. In a mouse model of steroid-associated osteonecrosis, hydrogen-rich water improved trabecular architecture and bone perfusion by upregulating the ACOD1-itaconate pathway — a specific immunometabolic mechanism reproducible with dimethyl itaconate supplementation alone.
• Zhu S et al. (2025), Bone. PMID: 41224067. A four-month simulated-high-altitude bone study in mice. Hydrogen-rich water preserved bone structure and reduced multi-organ damage by partially reversing hypoxia-induced gut dysbiosis — proposing a "gut-bone axis" route.
• Sun Y et al. (2013), Osteoporosis International. PMID: 22648000. The foundational microgravity-bone study. In a hindlimb-suspension rat model, hydrogen-rich water preserved bone mineral density and mechanical strength at femur and lumbar vertebra, with corresponding shifts in oxidative-stress markers and the RANKL/OPG ratio.
• Johnsen HM et al. (2023), Molecules. PMID: 38067515. A 2023 review of 81 clinical trials and 64 scientific publications on human hydrogen therapy. The broadest current synthesis of where the human evidence base actually sits — useful background for any reader who wants the field-wide context before reading any individual bone paper.
• Paparella R et al. (2026), Acta Paediatrica. PMID: 41482991. A 2026 mini-review of medical gases (including molecular hydrogen) as regulators of paediatric endocrine and neurodevelopmental pathways. Includes a section on bone biology, osteogenesis, and osteoclast activity in the context of redox-active gasotransmitters.
• Zanini D et al. (2021), Experimental Gerontology. PMID: 34601077. A 6-month randomized controlled pilot trial of hydrogen-rich water in 40 adults over 70. Favorable signals on telomere length, brain metabolism, and lower-body strength — a bone-relevant proxy. Bone density was not measured directly. No adverse events were reported across six months.
• Ohsawa I et al. (2007), Nature Medicine. PMID: 17486089. The selective-antioxidant proposal in a rat stroke model — the conceptual foundation every bone paper above references when explaining why a small diffusible molecule shows up in a bone-loss model at all.

References

1. An Y, Zhang H, Zhang Y, Zhang S, Zheng L, Shao H, Du W, Cheng L, Sun W, Ma J, Ruan Y, Xu J, Qin L. Hydrogen reshapes the senescent microenvironment of callus to enhance the healing of anti-osteoporotic-drug-induced atypical femoral fracture. Biomaterials. 2026;334:124287. PMID: 42143430. DOI: 10.1016/j.biomaterials.2026.124287.
2. An Y, Zheng L, Zhang S, Zhang H, Zhang Y, Shao H, Tong W, Chen Z, Yao H, Wen Z, Xu S, Li Y, Tian Q, Cheng L, Sun W, Qin L, Xu J. Hydrogen activates ACOD1-itaconate pathway to ameliorate steroid-associated osteonecrosis. Biomaterials. 2025;323:123428. PMID: 40411985. DOI: 10.1016/j.biomaterials.2025.123428.
3. Zhu S, Hao D, Chen Y, Shi Z, Zhong Y, Zhang F, Tang F, Wang S, Wu Y. Hydrogen intervention attenuates chronic hypoxia-induced bone degeneration and multi-organ damage via modulation of the gut microbiota. Bone. 2025;203:117718. PMID: 41224067. DOI: 10.1016/j.bone.2025.117718.
4. Sun Y, Shuang F, Chen DM, Zhou RB. Treatment of hydrogen molecule abates oxidative stress and alleviates bone loss induced by modeled microgravity in rats. Osteoporosis International. 2013;24(3):969-978. PMID: 22648000. DOI: 10.1007/s00198-012-2028-4.
5. Carnovali M, Banfi G, Mariotti M. Molecular Hydrogen Prevents Osteoclast Activation in a Glucocorticoid-Induced Osteoporosis Zebrafish Scale Model. Antioxidants (Basel). 2023;12(2):345. PMID: 36829904. DOI: 10.3390/antiox12020345.
6. Yoneda T, Tomofuji T, Kunitomo M, Ekuni D, Irie K, Azuma T, Machida T, Miyai H, Fujimori K, Morita M. Preventive Effects of Drinking Hydrogen-Rich Water on Gingival Oxidative Stress and Alveolar Bone Resorption in Rats Fed a High-Fat Diet. Nutrients. 2017;9(1):64. PMID: 28098768. DOI: 10.3390/nu9010064.
7. Zanini D, Todorovic N, Korovljev D, Stajer V, Ostojic J, Purac J, Kojic D, Vukasinovic E, Djordjievski S, Sopic M, Guzonjic A, Ninic A, Erceg S, Ostojic SM. The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: A randomized controlled pilot trial. Experimental Gerontology. 2021;155:111574. PMID: 34601077. DOI: 10.1016/j.exger.2021.111574.
8. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine. 2007;13(6):688-694. PMID: 17486089. DOI: 10.1038/nm1577.

This article is provided for educational and general wellness purposes only and should not be considered medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before beginning any new wellness practice, especially if you have a medical condition, are pregnant or nursing, or take prescription medications.